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Background: HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both
artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART). EFV, NVP,
artemether and lumefantrine are substrates, inhibitors or inducers of CYP3A4 and CYP2B6, creating a potential for
drug-drug interactions. The effect of EFV and/or NVP on lumefantrine pharmacokinetic profile among HIV-malaria
co-infected patients on ART and treated with AL was investigated. Optimal lumefantrine dosage regimen for patients
on EFV-based ART was determined by population pharmacokinetics and simulation.
Methods: This was a non-randomized, open label, parallel, prospective cohort study in which 128, 66 and 75 HIV-malaria
co-infected patients on NVP-based ART (NVP-arm), EFV-based ART (EFV-arm) and ART naïve (control-am) were enrolled,
respectively. Patients were treated with AL and contributed sparse venous plasma samples. Pharmacokinetic analysis of
lumefantrine was done using non-linear mixed effect modelling.
Results: Of the evaluated models, a two-compartment pharmacokinetic model with first order absorption and lag-time
described well lumefantrine plasma concentrations time profile. Patients in the EFV-arm but not in the NVP-arm had
significantly lower lumefantrine bioavailability compared to that in the control-arm. Equally, 32% of patients in the EFV-arm
had day-7 lumefantrine plasma concentrations below 280 ng/ml compared to only 4% in the control-arm and 3% in the
NVP-arm. Upon post hoc simulation of lumefantrine exposure, patients in the EFV-arm had lower exposure (median (IQR))
compared to that in the control-arm; AUC0-inf; was 303,130 (211,080–431,962) versus 784,830 (547,405–1,116,250);
day-7 lumefantrine plasma concentrations was: 335.5 (215.8-519.5) versus 858.7 (562.3-1,333.8), respectively. The
predictive model through simulation of lumefantrine exposure at different dosage regimen scenarios for patients
on EFV-based ART, suggest that AL taken twice daily for five days using the current dose could improve
lumefantrine exposure and consequently malaria treatment outcomes.
Conclusions: Co-treatment of AL with EFV-based ART but not NVP-based ART significantly reduces lumefantrine
bioavailability and consequently total exposure. To ensure adequate lumefantrine exposure and malaria treatment
success in HIV-malaria co-infected patients on EFV-based ART, an extension of the duration of AL treatment to five days
using the current dose is proposed.
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Malaria and HIV/AIDS are highly prevalent in sub-
Saharan Africa, accounting for almost 9% of the total dis-
ease burden and causing more than two million deaths
each year [1-3]. In Tanzania, the prevalence of malaria and
HIV/AIDS in adults (aged 15-49 years) is 5.3 and 5.1%,
respectively [4]. Although, the epidemiology of HIV and
malaria infections differs considerably, their geographical
distributions do overlap, and co-infection is common
among patients [2,3,5]. One of the critical areas of over-
lap between HIV/AIDS and malaria is the potentiality
for drug-drug interactions (DDIs) between antiretroviral
(ARVs) and anti-malarial drugs. Interactions between
ARVs, such as non-nucleoside reverse transcriptase in-
hibitors (NNRTIs) or protease inhibitors (PIs) and anti-
malarial drugs, especially those that are metabolized by
cytochrome P450 enzymes (CYP450) are of particular
concern [6-10].
Nevirapine (NVP) and efavirenz (EFV) has been the
most widely used NNRTIs in the management of HIV
infection particularly in resource-limited settings, in-
cluding Tanzania [11,12]. However, due to the reported
toxicities and ineffectiveness of NVP in the treatment of
HIV-TB co-infected patients, NVP is no longer recom-
mended as part of default regimen [11-14]. Based on
World Health Organization (WHO) recommendation,
currently, EFV-based antiretroviral therapy (ART) is a
preferred option for initiating treatment in ART-naïve pa-
tients in most developing countries, including Tanzania
and developed countries [11,13,14].
Equally, in all areas of malaria endemicity, WHO re-
commends the use of artemisinin-based combination
therapy (ACT) as the first-line treatment for uncompli-
cated falciparum malaria [15]. Among ACT, artemether-
lumefantrine (AL) is one of the most widely used drugs
for the treatment of uncomplicated falciparum malaria
in endemic countries [16].
Artemether, lumefantrine, EFV, and NVP are all meta-
bolized by CYP450 enzyme systems, therefore predis-
posing them to possible DDIs. Artemether is metabolized
to dihydroartemisinin (DHA) by CYP2B6, CYP3A4/5
and CYP2A6 [17]. DHA is rapidly inactivated to α-
dihydroartemisinin- β glucuronide through glucuronida-
tion via UDP-glucuronosyltransferases isoforms, UGT1A9
and UGT2B7 [18]. Lumefantrine is mainly metabolized by
CYP3A4 to desbutyl-lumefantrine [19]. EFV and NVP are
metabolized by CYP2B6 and CYP3A4, and are also potent
inducers of these enzymes [20-23]. Drugs that induce or
inhibit CYP450 enzymes may decrease or increase con-
centrations of concurrently administered drugs leading to
treatment failure or drug toxicities, respectively [24]. So
far, there is limited and inconclusive information on the
potential interactions between anti-malarial drugs and
NNRTIs [7-10].Therapeutic efficacy of AL depends largely on the area
under the plasma concentration time curve (AUC) above
the minimum parasiticidal concentration of lumefantrine
[19,25]. Day-7 lumefantrine plasma concentration is a
surrogate marker of AUC [19]. Thus, any factor lowering
day-7 lumefantrine plasma concentration could potentially
increase the risk of treatment failure and emergence of
drug resistance. Equally, EFV induction of CYP3A4 is
influenced by CYP2B6*6 genotype, in a gene-dose de-
pendent manner. Studies conducted in Tanzania show
that allele frequency of CYP2B6*6 among Tanzanian are
about 34-42% [26,27].
This study reports on the pharmacokinetic interaction
between lumefantrine and EFV and/or NVP in HIV-
infected patients with uncomplicated falciparum malaria,
stable on ART. Equally, optimal lumefantrine dosage
regimen for patients on EFV-based ART was determined
using mathematical modelling.
Methods
Study design, subjects and ethical approval
This was a prospective, open label, parallel, non-randomized,
pharmacokinetic drug interaction study with three arms.
It was conducted at Bagamoyo District Hospital-HIV
clinic in Tanzania between May 2010 and September
2012. HIV-1-infected patients with uncomplicated falcip-
arum malaria were recruited. The study population was
sub-grouped into three arms: patient taking 200 mg NVP
twice daily (NVP-arm, n = 128) or 600 mg EFV once
at night (EFV-arm, n = 66)-based ART for at least two
months and those not yet on ART (control-arm, n = 75).
Patients were enrolled in the study if they met the fol-
lowing criteria: HIV-1 infection; age ≥18 years; auxiliary
temperature ≥37.5°C or history of fever within 24 hours
before visiting the clinic and with at least any of the fol-
lowing signs and symptoms: chills, sweats, headaches,
muscle aches, nausea, vomiting, diarrhoea, body weak-
ness, poor appetite, pallor, and enlarged spleen. Other
patient-related parameters for inclusion in the study
were haemoglobin (Hb) ≥7 g/dl; body weight ≥35 kg;
and, microscopically confirmed Plasmodium falciparum
infection.
The exclusion criteria included: signs of severe mal-
aria; history of allergic reaction to any of the drug used
in the study; evidence of chronic diseases such as renal
and liver failure; use of anti-tuberculosis drugs for at
least three months prior to enrolment; being on anti-
malarial drugs four weeks prior to enrolment; being
pregnant or nursing mother. In addition, use of alcohol,
caffeine, drugs which induce or inhibit CYP3A4 and
CYP2B6, prescription drugs, herbal medicines, oral con-
traceptives pills, grape fruits or juice was not permitted.
Electrocardiogram, liver and kidney function tests, Hb
test, blood smear for malaria parasite and pregnancy test
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rolment in the study.
The study was approved by Muhimbili University of
Health and Allied Sciences (MUHAS) Research and Ethics
Committee. The study was conducted according to good
clinical practice. The purpose of the study and its proce-
dures were clearly explained to all study participants. A
written informed consent was obtained from all partici-
pants prior to enrolment.
Study procedures
Drug dosing, blood sampling and processing for
pharmacokinetics
Patients meeting the inclusion criteria were enrolled and
took the full dose (three-day course) of AL (Coartem® con-
taining 80 mg artemether and 480 mg lumefantrine,
Novartis Pharma AG, Basel, Switzerland) at 0, 8, 24, 36, 48,
and 60 hours. The first and fifth doses of AL were adminis-
tered under direct observed therapy (DOT) with 250 ml of
milk (3.5% fat). The other four doses were taken at home.
All patients were given verbal instructions on dosing inter-
vals and on the importance of combining treatment with
fatty meals. Additionally, patients were supplied with ten
extra 250-ml packets of milk (3.5% fat) to be taken with
the rest of the doses at home. Paracetamol was adminis-
tered to all febrile patients. Patients were encouraged to re-
turn to the study site any time they felt ill. Patients who
failed to return on the scheduled day were visited and
assessed at home. If the study nurse failed to locate the pa-
tient’s house, they were classified as lost to follow-up. Any
additional medications taken by patient during the study
period were all documented in a case report form (CRF).
A pre-defined time schedule for blood sample collec-
tion was prepared and randomly assigned to patients. A
maximum of six blood samples were collected from each
patient over a 14-day time span. Emphasis was on the
elimination phase, thus, collection of blood samples
started after the fifth dose of AL administration. Prior to
AL treatment 4, 2 and 1 ml of blood were collected in
heparinized EDTA and in plain vacutainer tubes for
lumefantrine, NVP-EFV and for clinical chemistry test,
respectively. Just before taking the fifth dose of AL
(48 hours), a cannula was inserted into a vein of the
patient’s arm and 4 ml of blood sample was drawn
for lumefantrine plasma level determination (trough
concentration). After a patient has taken the fifth
dose of AL, a maximum of three blood samples were
collected from each patient at any of the following
time points; 49, 50, 51, 52, 53, 54, 56, 58, 60, 72, 96,
and 120 hours (sparse sampling). Similarly, all patients
contributed blood samples on days 7 and 14 except for
those who missed the scheduled visits.
The collected blood samples were kept in a cool box
with an ice and were sent within 15 minutes to thelaboratory at Ifakara Health Institute-Bagamoyo Research
and Training Centre (IHI-BRTC) for centrifugation and
storage. Blood samples were centrifuged (×2,000 g for
10 min) and plasma was transferred into the cryotube
and stored in -80°C freezer. The plasma samples were
transported on dry ice to MUHAS-Sida Bio-analytical
laboratory in Dar es Salaam for analysis.
Drug analysis
All blood samples were analysed at MUHAS-Sida Bio-
analytical laboratory. Lumefantrine plasma concentrations
were quantified using high performance liquid chromato-
graphy (HPLC) method with UV detection as previously
reported [28]. The coefficients of variation (CV %) during
the analysis of lumefantrine was 2.5, 4.2 and 1.8% at 100,
1000, and 8,000 ng/ml, respectively. The observed ac-
curacy during this analysis was -4.6, 3.6 and 7.4% at 100,
1000, and 8,000 ng/ml, respectively. The lower limit of
quantification (LLOQ) for lumefantrine was 50 ng/ml.
NVP and EFV were extracted from human plasma with
protein precipitation procedure and were quantified using
HPLC method with UV detection as earlier described,
with minor modification [29]. The CV (%) during the ana-
lysis of EFV was 2.4, 0.7 and 1.4%, and for NVP was 2.1,
1.1 and 0.9% at 750, 5,000 and 12,500 ng/ml, respectively.
The observed accuracy during the analysis of EFV was 5.2,
3.3 and 0.8% and for NVP was 5.5, 4.7and 2.4 at 750,
5,000 and 12,500 ng/ml, respectively. The lower limit of
quantification for NVP and EFV was 250 ng/ml.
Adverse effects monitoring
Clinical chemistry tests and standardized questionnaires
were all used to determine possible adverse effects of ad-
ministered drugs on each visit.
Pharmacokinetic and statistical analysis
Statistical analysis
Sociodemographic and clinical characteristics data were
analysed using the Statistical Package for Social Sciences
(SPSS) (version 16.0) software. Categorical variables were
compared by Chi-square test. The one-way analysis of vari-
ance (ANOVA) test was used to compare the continuous
variables between the three arms. Descriptive statistics were
also used where appropriate. Baseline patient’s characteris-
tics were summarized as medians with interquartile range
(IQR) and means with standard deviation (SD). Post hoc
pharmacokinetics parameters were expressed as medians
(IQR) and statistical comparisons were done using one-way
ANOVA after logarithmic transformation. A two-tailed
P-value of <0.05 was considered statistically significant.
Pharmacokinetic analysis
Among the analysed samples, 17 (1.1%) displayed concen-
tration below the LLOQ and were not used for population
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kinetics was initially explored by plotting the plasma con-
centration time profiles on logarithmic scale. Models were
fitted to the data through non-mixed effects modelling
(NONMEM) (version 7.2, Icon Development Solutions)
sub-routines ADVAN2 TRANS1 (one-compartment model)
and ADVAN4 TRANS4 (two-compartment model). The
pearl-speaks- NONMEM program (PSN version 3.7.5),
R statistical program (version 3.0.1) and the Xpose pro-
gram (version 4.4.0) were used for visual and quantitative
diagnostics.
Different types of absorption models were tested includ-
ing: zero order absorption, first order absorption with lag
time and transit compartment absorption models (with
fixed number of absorption compartments from one to
ten). The pharmacokinetics parameters estimated in the
final model were: clearance (CL/F), apparent volume of
distribution in the central compartment (Vc/F), peripheral
apparent volume of distribution (Vp/F), absorption rate
constant (Ka), inter-compartmental clearance (Q/F) and
absorption lag time (tlag). All the parameter values, except
Ka and tlag were standardized for total body weight using
the allometric scaling formula; Tvθ = θ×[weight(kg)/70]n,
where θ and Tvθ are typical parameter values for po-
pulation and body weights, respectively; n is exponent of
value ¾ for clearances and 1 for volumes [30].
Sensitivity/identifiability of model parameters was as-
sessed by fixing the parameter values to double or half
of those reported in the literature and rerunning the
model fitting. A parameter was considered identifiable if
such tweaking resulted in changes in objective function
values (OFVs) for more than 3.84 units. Initial parameter
values were obtained from a study conducted by Tarning
et al. [31]. Since for oral kinetic data, bioavailability pa-
rameter (F) is usually unidentifiable, its value was fixed
to 1 (100% bioavailability) to allow accurate estimation
of other parameters. Between subject and between occa-
sions variation (random effects) for all the fixed effect
parameters was tested. Exponential models were as-
sumed for all the random effects. Sequential stochastic
model building procedure was used, whereby one random
effect parameter was evaluated at a time. A combined
(additive and proportional) error model was used to ac-
count for residual variation in the measured lumefantrine
concentrations. A better model was chosen based on likeli-
hood ratio test by using the OFVs computed by NONMEM
program. For a hierarchical model, a decrease in OFVs by
more than 3.84 units (equivalent to P value <0.05) was
considered significant improvement to model fit. The
first-order conditional estimation (FOCE) of pharmacoki-
netic parameters was used throughout the modelling.
The full covariate model building approach was used
so as to decide which parameter-covariate relationships
were statistically and clinically significant [32,33]. Initialparameter covariate relationships were chosen based on
exploratory graphics (random effects versus covariate plots)
and mechanistic plausibility of parameter-covariate rela-
tionship. Since ART can influence clearance and bio-
availability of lumefantrine simultaneously, thus, type of
concomitant ART were included as covariate on both pa-
rameters in the full model. No other parameter-covariate
relationships were included. The estimated fixed effect pa-
rameters and their covariance (uncertainty) were used to
simulate fixed effect parameter values for 1,000 patients.
The resulting posterior distribution of the parameters
(mean and 95% confidence interval) relative to the refer-
ence values (population typical values) was used to decide
on the clinical and statistical significance of the parameter-
covariate relationship. Finally, the full model was reduced
to the final model by removing relationships that were not
statistically significant or clinically important.
Precision of the model parameters was obtained through
the NONMEM covariance functionality. Evaluation of the
final model was done using goodness-of-fit plots, visual
predictive check (VPC) and confidence intervals (CI) or
relative standard errors (RSE) of the estimated parameters.
Pharmacokinetic simulations and post hoc calculations for
AUC and Cmax
The final model parameters (including random effects) were
used to simulate pharmacokinetic parameters AUC(0-inf),
Cmax, Tmax and day-7 lumefantrine plasma concentrations
at different dosage scenarios: 480 mg twice daily for three
days (normal dosing); five or seven days; and, 1,200 mg
twice daily for three days. In each scenario, 9,960 stochas-
tic simulations were made. The obtained AUC(0-inf), Cmax,
Tmax, and day-7 lumefantrine plasma concentrations were
compared between the arms through visual inspection of
box plots, summary statistics and ANOVA after logarith-
mic transformations.
Results
Baseline characteristics and treatment outcomes
A total of 269 HIV-infected patients with uncomplicated
falciparum malaria were enrolled. No significant diffe-
rence was observed between patients’ baseline character-
istics for the three arms studied, except in the case of
patients’ age (P = 0.015), Hb (P = 0.036) and CD4+ cell
counts (P = 0.002) (Table 1). The results for malaria
treatment outcomes have been reported elsewhere [34].
AL was well tolerated in all enrolled patients; the ob-
served and reported drug side effects were mostly mild
in severity.
Pharmacokinetics of lumefantrine
A total of 1,514 venous plasma samples were available for
analysis and comparison. Lumefantrine plasma concentra-
tion time profile for the three arms studied is presented in
Table 1 Patients baseline characteristics
Parameters ARMS
Control (n=75) Nevirapine (n=128) Efavirenz (n=66) P value
Sex (female) % 65 79.5 52.3
Median age in years 38 (19–64) 42 (21–67) 43 (39–66) 0.015
Temperature mean, SD ± OC 38.1 ± 0.8 37.8 ± 1.3 38.3± 0.9 0.485
Median weight (IQR) 56 (41–92) 55 (41–78) 58 (36–84) 0.953
Median (range) parasite density/μL 1280 (560–4040) 4040 (600–261520) 3440 (480–126960) 0.564
Haemaglobin (g/dL) median (IQR) 13.9 (12.2-15.2) 12.1 (11.2-13.5) 12.3 (10.2-13.6) 0.036
CD4+ count (x106/L) median (IQR) 402 (66–964) 354 (19–1781) 298 (9–694) 0.002
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on a logarithmic scale indicated a two-compartment phar-
macokinetics. Data for this study was well described by
two-compartment pharmacokinetic model with first order
absorption and lag-time.
The full covariate model building approach identified
concomitant EFV and NVP as statistically significant co-
variates on bioavailability but not on clearance (Figure 2).
It can be implied from the full model that EFV co-
treatment causes clinically important decrease in lu-
mefantrine bioavailability. Although NVP is shown to
increase lumefantrine bioavailability, data were insuffi-
cient to conclude the clinical importance of this effect.
EFV and NVP co-treatment as important covariates on
the bioavailability of lumefantrine and other final model
pharmacokinetics parameter estimates are indicated in
Table 2. Evaluations of the final model did not show any
model misspecification. The computed η-shrinkage was
high for most of the computed pharmacokinetics parame-
ters (defined as ≥30%), except for Q/F (23%) and F (5%)
(Table 2). The performance of the final model was highly
predictive as enlightened by the VPC plots (Figure 3).Figure 1 Lumefantrine concentration time profiles for HIV-malaria-
co-infected- patients on antiretroviral drugs and those not yet on
antiretroviral drugs.Pharmacokinetics of lumefantrine in patients treated with
EFV-based ART
The raw data indicated that 32 and 4% of patients in the
EFV-arm and in the control-arm, respectively, had day-7
lumefantrine plasma concentrations below the suggested
cut-off value of 280 ng/ml. The simulated data indicated
that, at the current AL dosing, the pharmacokinetic pa-
rameters AUC0-inf and Cmax were lower by 61.3 and
61.1%, respectively, compared with that in the control-
arm (Table 3). No statistical significant difference was
observed between the Tmax of this arm and that of the
control-arm (P = 0.86). Day-7 lumefantrine median (IQR)Figure 2 Estimated parameters and covariate effects along with
uncertainty relative to the reference value. The light grey shaded
region represents clinically irrelevant effect (+/- 20%) region. Numbers
outside the shared region represent the approximate probability of the
effect to be clinically relevant. Numbers inside the region represent the
probability distribution within the clinically irrelevant region on either
side of the reference line. FARM1 = Bioavailability for NVP-arm; FARM2 =
Bioavailability for EFV-arm; CLARM1 = clearance for NVP-arm; CLARM2 =
clearance for EFV-arm.
Table 2 Parameter estimates describing lumefantrine population pharmacokinetics for HIV-malaria co-infected patients
treated with artemether-lumefantrine




Ka (hr-1) Absorption rate constant 0.032 (0.029-0.034) 29% (18) (30)
Vc/F (liters) Central volume 25.6 (16.21-34.99) 82% (24) (51)
CL/F (liters/hr) Clearance 4.54 (3.913-5.167) 0* 19% (22) (44)
Q/F (liters/hr) Inter-compartmental exchange Clearance 1.23 (0.99-1.47) 27% (24) (23)
Vp/F (liters) Peripheral Volume 203 (167.13-238.87) 39% (22) (37)
t lag (hr) Absorption lag time 1.45 (1.25-1.65 ) 0*
F1 Bioavailability (population typical value) 1* 47% (11) (5)
F1 EFV Relative bioavailability for patients on Efavirenz 0.42 (0.34-0.5)
F1 NEV Relative bioavailability for patients on Nevirapine 1.32 (1.08-1.52)
ADD Additive residual error 26.30 (4.15-48.44)
PROP Proportion residual error 0.083 (0.06-0.10)
RSE, relative standard error; CI, confidence intervals; BSV, Between Subject Variability; BOV, Between Occasion Variability; *,Fixed to this value.
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with that in the control-arm (P < 0.001) (Table 3).
Pharmacokinetics of lumefantrine in patients treated with
NVP-based ART
In the present study, only 3% of patients in the NVP-arm
had day-7 lumefantrine plasma concentration below theFigure 3 Visual predictive checks of the final two-compartment-mode
The aforementioned visual predictive checks are for HIV-malaria co-infected p
those not yet on antiretroviral therapy (control-arm) treated with artmether-lutherapeutic cut-off point of 280 ng/ml. The simulated data
indicated that, at the current AL dosing, AUC0-inf and Cmax
were higher by 24.6 and 24.8%, respectively, in patients on
NVP-based ART compared with that in the control-arm
(Table 3). There was non-significant difference in the
day-7 lumefantrine median (IQR) plasma concentra-
tions between the NVP-arm and control-arm (P = 0.063).l describing the population pharmacokinetics of lumefantrine.
atients on NVP-based ART (NVP-arm), EFV-based ART (EFV-arm) and
mefantrine.
Table 3 Simulated lumefantrine pharmacokinetics parameters in HIV-malaria co-infected patients treated with AL (9960 simulations)
Parameters Control-arm Nevirapine-arm Efavirenz-arm
Dose 480 mg bid 3 days 480 mg bid 3 days 480 mg bid 3 days 480 mg bid 5 days 480 mg bid 7 days 1200 mg bid 3 days
Cmax (ng/ml) 8192.7 (5664.3 - 11896.8) 10229 (7173.4 - 14606) 3182.2 (2198.4 - 4586.1) 3678.2 (2609.7 - 5150.7) 3887.5 (2690.4 - 5531.4) 7955 (5496.2 - 11464)
AUC0-inf (ng.hr/ml) 784830 (547405–1116250) 977645 (688477–1383975) 303130 (211080–431962) 513760 (359212.5 - 713715) 755090 (528277–1086525) 757835 (527702–1079925)
Tmax (hr) 66.1 (63.6 - 67.7 ) 66.1 (60.0 - 67.7 ) 66.1 (60.4 - 67.6) - - -
Simulated day 7 plasma
concentration (ng/ml)
858.7 (562.3 - 1333.8) 1090.3 (704.4 - 1680.4) 335.5 (215.8 - 519.5) 1039.4 (678.1- 1552.8) 1079.2 (694.1- 1689.6) 838.9 (539.6 - 1298.9)
Observed day 7 plasma
concentration (ng/ml)
970 (562.1 - 1729) 1125 (638.8 - 1913) 300.4 (220.8 - 343.1) - - -
AL, artemether-lumefantrine; bid, after every 12hrs; AUC0-inf, plasma AUC from 0 hour extrapolated to infinity; Cmax, maximum plasma concentration; Tmax, time to reach maximum plasma concentrations. The presented
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between the Tmax of this arm and that in the control-arm
(P = 0.86) (Table 3).
Dose regimen simulations for patients on EFV-based ART
Extending the duration of treatment of AL from three to
five days using the current dose taken twice daily, the
simulated AUC0-inf and Cmax were slightly lower com-
pared to that observed in the control-arm. Nonetheless,
the simulated day-7 lumefantrine plasma concentrations
in the EFV-arm were comparable to that observed in the
control-arm.
Equally, when the duration of treatment of AL was ex-
tended from three to seven days while using the current
dose and taken twice daily or escalation of lumefantrine
dose to 1,200 mg (2.5 times the normal dose) taken
twice daily for three days, the simulated AUC0-inf and
Cmax and day-7 lumefantrine plasma concentrations
were comparable to that observed in the control-arm.
These results are summarized in Table 3 and Figure 4.
Discussion
A fixed-dose combination of ACT, such as AL, is most
widely used in the treatment of uncomplicated and
multidrug-resistant falciparum malaria in areas of ende-
micity, including Tanzania [16,35,36]. AL has gained its
popularity as the drug of choice in malaria-endemic coun-
tries due to its safety and efficacy [37,38]. Few studies have
reported on the potential effect of NNRTIs on the
pharmacokinetics profile of AL in either HIV-infected pa-
tients or healthy volunteers without malaria [7-10]. The
present study evaluated the pharmacokinetics profile of
lumefantrine in HIV-infected patients on ART and those
not yet on ART with uncomplicated falciparum malaria
treated with AL.
The major finding from this study is the significant re-
duction of lumefantrine bioavailability, exposure and
day-7 plasma concentrations among patients on EFV-
based ART compared to ART naïve patients. On the
contrary, lumefantrine bioavailability, total exposure, and
day-7 plasma concentrations were higher among pa-
tients on NVP-based ART compared to ART naïveFigure 4 Simulated lumefantrine pharmacokinetic parameters at different do
treatment. The box and whiskers represent 95% confidence interval of the mepatients, although, this differences did not reach statis-
tical significance.
The observed results in EFV-treated patients are in
agreement with results reported from studies conducted
in Uganda and USA [7,10]. However, some differences
were observed from Huang et al. study which could be
accounted for by sample size, age, sex, disease status
(healthy versus HIV-malaria co-infection), ethnicity, and
genetic. The observed results in the EFV-arm appear to
be mediated through a pharmacokinetics interaction be-
tween lumefantrine and EFV, via induction of either
gastrointestinal or hepatic CYP3A4 or both. The induc-
tion of CYP3A4 by EFV is reported to be concentration
and time dependent [22,39,40], and is via the human
nuclear pregnane X receptor (hPXR) and the human con-
stitutive androstane receptor (hCAR) [22,23]. Transactiva-
tion of hCAR and hPXR receptors in return increases the
functional activity of CYP3A4 [22,23]. Thus, the persistent
induction of CYP3A4 by EFV could explain the low
lumefantrine exposure in the EFV-arm [39,40]. Accord-
ingly, the EFV-arm results are in keeping with what has
been reported by others [41,42].
On the other hand, the findings obtained in the NVP-
arm are consistent with the results from a South African
study [9], but different from a Ugandan study [10] in
which lumefantrine day-7 plasma concentrations and
exposure were decreased, although the decrease was not
statistically significant. Study design, food intake, pa-
tient’s immune status, patient’s body weight, smoking,
alcohol intake and disease status (HIV only versus HIV-
malaria co-infection) might have contributed to the ob-
served differences. Lumefantrine AUC increases with
subsequent dose and its absorption is enhanced by food
intake, particularly fat meal, just as small as 1.2 g of fat
is enough to increase the absorption of lumefantrine to
about 16-fold [43]. In the present study, all patients were
supplied with full cream milk (3.5 g fat) and had to take
the latter before dosing with AL (all doses). In the Ugandan
study patients were asked to take the five doses of AL
(among the six doses of AL) at home while encouraged to
take each dose with milk, only the last dose was given with
fatty meal at the clinic [10]. In addition, the Ugandansage scenarios for HIV-malaria-co-infected- patients on efavirenz-based
an and the first and third quartiles of the simulated.
Maganda et al. Malaria Journal  (2015) 14:179 Page 9 of 11study enrolled only those patients with CD4 cell count
of ≤200 cells/cu mm, while in the present study par-
ticipants in the NVP-arm had a median CD4 cell counts
of >350 cell/cu mm [10]. Thus, the differences in immune
status among patients involved in the two studies could be
accounting for the observed differences. Patients with low
CD4 cell counts are often sick and frail with reduced food
intake, hence compromising AL absorption.
Although NVP and EFV are reported to be both an in-
ducer of CYP3A4 and CYP2B6, the induction capacity is
reported to be disproportional [22,23]. EFV is reported to
be a five times more potent inducer of CYP3A4 than NVP
at a given drug concentration [23]. The differences in the
induction capacity of CYP3A4 enzyme might explain the
observed differences in the reduction of lumefantrine bio-
availability, exposure and day-7 plasma concentrations by
the two drugs. Similarly, Mouly et al. reported non-induc-
ibility of CYP3A4 by NVP. HIV-infected patients on ART
were involved [44]. Further research exploring the possible
mechanism of interaction between NVP and lumefantrine
is highly required, as this study was not designed to ex-
plore the aforementioned interactions.
The objective of using anti-malarial drugs for treatment
of uncomplicated malaria is to clear all parasites from the
body, thus cure the infection [19]. The AUC of lumefan-
trine above the minimum parasiticidal concentration is
the determinant of treatment response in patients with
uncomplicated malaria and reflects the degree of exposure
of parasite to lumefantrine after artemether is cleared
[19,25]. Accordingly, low lumefantrine exposure is asso-
ciated with increased risk of malaria treatment failure and
emergence of drug-resistant parasites [19,45].
The results of the present study are in agreement with a
recent published study which reported high rate of para-
sitaemia recurrence in HIV-malaria co-infected patients
on EFV-based ART as compared to those on NVP-based
ART or not yet on ARTand treated with AL [34]. This ob-
servation is of concern, especially with the escalated use of
EFV in HIV-infected patients in Tanzania, where malaria
is also endemic [11]. On the other hand, EFV induction of
CYP3A4 is influenced by CYP2B6*6 genotype, in a gene-
dose dependent manner [39,40]. Previous studies have
indicated that allele frequency of CYP2B6*6 among
Tanzanian is about 34-42 [26,27]. This calls for a conti-
nued usage of NVP among HIV-infected patients (without
potential fatal side effects) in malaria-endemic areas, since
phasing out this ARV may create challenges in the
management of uncomplicated malaria in this population.
Alternatively, based on our finding, increasing the dur-
ation of malaria treatment in patients receiving EFV-based
ART may salvage the risk of sub-therapeutic plasma ex-
posure of lumefantrine and hence, treatment failure.
A new dosage regimen of AL that would achieve the
therapeutic efficacy in patients on EFV-based ART withuncomplicated falciparum malaria was simulated using the
final predictive model. The predictive model through simu-
lation suggested that escalating lumefantrine dose to 2.5
times the normal dose taken twice daily for three days
would achieve the targeted therapeutic plasma concentra-
tion in this population comparable to that in the control-
arm. Importantly, in a recent published study an increment
of lumefantrine dose to 250% was proposed for malaria pa-
tients co-treated with EFV-based ART [46]. Nonetheless,
lumefantrine absorption is dose-dependent and its oral ab-
sorption decrease as doses (amount) increases. It has been
also reported that lumefantrine absorption is close to satu-
ration at the current doses in the standard regimen [47].
Thus, any increase in lumefantrine doses may result into
kinetics shifting from first order to zero order absorption
rate leading to unexpected under-dosing of patients.
The predictive model also suggested that increasing the
duration of treatment from three to five days or seven
days would achieve the targeted lumefantrine exposure
and day-7 plasma concentrations above the minimum par-
asiticidal concentration [25]. Similarly, in a study from
Thailand, increase of AL duration of treatment from 60 to
96 hours, resulted into an increase of lumefantrine expo-
sure from 60 to 100%, respectively [48]. However, increa-
sing the duration of AL treatment to five or seven days
may be associated with reduced adherence and increased
risk of adverse events. Thus, achieving maximum malaria
cure rate and treatment adherence, a twice daily dose of
AL given for five days may be more appropriate than the
seven days for this population. Likewise, Tarning et al. in
their study suggested the same for pregnant women with
day-7 lumefantrine plasma concentration below the thera-
peutic cut-off value of 280 ng/ml [31].
Although, predictive models used in drug dosage regi-
men optimization may provide necessary information with
respect to quantitative understanding of dose exposure-
response relationship, whilst, accounting for patients’ be-
haviour such as adherence, nevertheless, this may not be
achieved in vivo due to non-linear relationship between
PK/PD, drug toxicity and poor adherence to treatment.
Thus, patient’s adherence to treatment and safety need to
be evaluated, before implementation of the proposed dos-
age regimen.
The final model described well the present data and is
highly predictive; the computed results for the fixed and
random effects are highly informative and robust. The
reported high η-shrinkage in this study could be contri-
buted by the sparseness of sampling [49].
Conclusion
Pharmacokinetics of lumefantrine in the present study
was best described with two-compartment models with
first order absorption and lag time. Co-administration of AL
with EFV-based ART but not NVP-based ART significantly
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exposure. Results from the predictive model suggested that;
extending the duration of AL treatment from three to five
days using the current dose taken twice daily will be ad-
equate for lumefantrine exposure and treatment success in
HIV-infected patients with uncomplicated falciparum mal-
aria on EFV-based ART. In addition, the observed low lume-
fantrine exposure in HIV-malaria co-infected patients on
EFV-based ART poses a significant challenge in treating
malaria in this population. Therefore, in malaria- and HIV-
endemic areas where AL is widely used, clinicians may be re-
quired to undertake a thorough assessment of patient’s eligi-
bility for ART initiation, before choosing an appropriate
NNRTI for initiation, as NVP may still be an appropriate
alternative.
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